December 04, 2019: Dr Reddy’s Laboratories launched Bortezomib for Injection (IV) 3.5 mg/vial for the treatment of certain types of cancers in adult patients, in the US market approved by the United States Food and Drug Administration (USFDA).
This product is for intravenous use only for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who already  received at least one prior therapy.
Each vial contains 3.5 mg bortezomib (as a mannitol boronic ester) that After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib. https://www.drugs.com/uk/bortezomib-dr-reddys-3-5-mg-powder-for-solution-for-injection-leaflet.html
